Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered MRI could revolutionize breast cancer screening without contrast dyes

NCT ID NCT07205276

Diagnosis Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether artificial intelligence can analyze non-contrast breast MRI scans to detect cancer early, avoiding the need for contrast agents that can be costly and risky. Researchers plan to enroll 30,000 women aged 30-70 and compare AI readings to standard radiologist interpretations. If successful, this approach could offer a safer, more accessible screening option, especially for women with dense breast tissue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Non-contrast multiparametric breast MRI with AI-based radiomics analysis
What this could lead to
If successful, this could provide a safer, more accurate breast cancer screening method that avoids contrast agents and works well for women with dense breast tissue.
What could go wrong
The AI model is still being developed and validated; it may not perform as well in real-world settings or across diverse populations. The trial is not yet recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: 1. Female, age 30-70 years 2. Completed breast MRI scan, including at least T2WI, DWI, and ADC sequences 3. Multimodal data acquired within the same time window (≤90 days) 4. A clear clinical outcome: pathologically confirmed or ≥12-24 months of negative follow-up 5. The time window between imaging examination and outcome determination was ≤90 days 6. Signed informed consent * Exclusion Criteria: 1. Absolute contraindications to MRI (pacemaker, cochlear implant, ocular metal foreign body, etc.) 2. Pregnant or lactating women 3. Recent history of breast surgery/radiotherapy (≤6 months) or imaging after neoadjuvant therapy 4. Substandard image quality (severe motion artifact, signal-to-noise ratio below threshold) 5. Incomplete clinical data or time window exceeded 6. Known breast cancer metastasis or recurrence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ai (artificial intelligence) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ai (artificial intelligence) Breast cancer detection Early detection of cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.